Thrombin Alfa (Recombinant) (Topical)

Brand names: Recothrom
Drug class: Antineoplastic Agents

Usage of Thrombin Alfa (Recombinant) (Topical)

Hemorrhage

Used topically as an aid in achieving hemostasis at accessible sites of oozing blood and minor bleeding from capillaries and small venules when control of bleeding using standard surgical measures (e.g., suture, ligature, electrocautery) is ineffective or impractical.

May be used alone or in conjunction with an absorbable gelatin sponge during various types of surgery (e.g., spinal surgery, liver resection, peripheral arterial bypass surgery).

Do not use for massive or brisk arterial bleeding. (See Contraindications.)

Relate drugs

How to use Thrombin Alfa (Recombinant) (Topical)

Administration

Topical Administration

Apply topically as a solution; do not inject. (See Contraindications.) Separate topical thrombin solutions from parenteral preparations to avoid inadvertent injection. (See Thrombosis under Cautions.) Do not leave reconstituted solutions in syringes as an intermediate step.

Apply directly to surfaces of bleeding tissue using a sterile syringe sprayer or spray pump; alternatively, may apply with an absorbable gelatin sponge. Consult manufacturer's instructions for proper assembly and use of the syringe sprayer or spray pump (available as part of the spray applicator kit).

When used in conjunction with an absorbable gelatin sponge, transfer solution to a sterile bowl or basin. Immerse sponge strips of the desired size in solution to allow complete saturation. Gently squeeze sponge strips to remove excess drug and apply to bleeding site in a single layer. Consult manufacturer's information for detailed instructions on use of absorbable gelatin sponge preparations.

Reconstitution

Using a needle-free transfer device, add 5 or 20 mL of the supplied diluent (0.9% sodium chloride injection) to a vial containing 5000 or 20,000 units, respectively, of lyophilized thrombin alfa (thrombin [recombinant]) to provide a solution containing 1000 units/mL. Gently swirl vial until powder is completely dissolved.

Draw reconstituted solution into a sterile syringe and apply auxiliary label indicating that the solution is for topical use only.

Use within 24 hours of reconstitution.

Dosage

Adults

Hemorrhage Topical

Volume of drug required to achieve hemostasis depends on total number of bleeding sites, surface area being treated, and method of application.

Hemostasis usually achieved within 10 minutes following a single application.

Warnings

Contraindications

  • Do not inject directly into circulatory system. (See Thrombosis under Cautions.)
  • Treatment of massive or brisk arterial bleeding.
  • Known hypersensitivity to thrombin alfa, hamster proteins, or any ingredient in the formulation.

    • Warnings/Precautions

    Warnings

    Thrombosis

    Risk of thrombosis if absorbed systemically. Do not inject directly into the circulatory system; serious complications including hypotension, systemic thrombosis, and death may result. (See Contraindications under Cautions.) Take appropriate precautionary measures to avoid inadvertent injection. (See Administration under Dosage and Administration.)

    Sensitivity Reactions

    Hypersensitivity

    Potential allergic reaction in patients with known hypersensitivity to snake proteins (due to use of snake-venom-derived prothrombin activator in production process).

    Antibody Formation

    Possible development of antibodies to thrombin alfa; risk of antibody development lower than that associated with bovine-derived thrombin. Relationship between antibody formation and clinically important adverse effects (e.g., excessive bleeding) not observed.

    Immunogenicity of thrombin alfa not affected by preexisting antibodies to bovine thrombin.

    Limited experience with repeated exposure to the drug.

    Specific Populations

    Pregnancy

    Category C.

    Pediatric Use

    Evaluated in a limited number of pediatric patients (12–17 years of age) undergoing burn wound excision prior to grafting. Manufacturer states safety and efficacy in pediatric patients <12 years of age not established.

    Geriatric Use

    No overall differences in efficacy or safety relative to younger patients, but increased sensitivity cannot be ruled out.

    Common Adverse Effects

    Incision site complications.

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords